This episode outlines the crucial process of compiling and submitting data to regulatory agencies, such as the FDA, following the completion of Phase 3 clinical trials. We explain the differences between the New Drug Application (NDA) for traditional small-molecule drugs and the Biologics License Application (BLA) for complex biologic therapies. We break down the structure and content of the electronic Common Technical Document (eCTD), the globally standardized format for regulatory submissions, and its five modules, each serving a specific purpose in presenting the drug's profile. We discuss the various types of information included in each module, from administrative details and summaries to comprehensive quality, non-clinical, and clinical data. Join us as we unpack the essential components of a successful regulatory submission.

This epi ...